Abbott Laboratories (ABT)

Abbott Laboratories (ABT $109.41)
- $109.41 P/E (TTM): 13.71X Cap: $190.05B
- View ABT Profile
- View Questions on ABT

{tplLang.businessdescription | toLang tLang}

{ profileData.description }

{tplLang.details | toLang tLang}

{tplLang.ceo | toLang tLang}

{profileData.profile.details.ceo}

{tplLang.employees | toLang tLang}

{profileData.profile.details.employees | numeraljs '0,0'}

{tplLang.issuetype | toLang tLang}

{profileData.profile.details.issuetype | asIssueType}

{tplLang.industryclassifications | toLang tLang}

{tplLang.sector | toLang tLang}

{profileData.profile.classification.sector}

{tplLang.industry | toLang tLang}

{profileData.profile.classification.industry}

{tplLang.toolname| toLang tLang}

There is no {tplLang.toolname| toLang tLang} currently available for {data.symbolstring}.

Abbott Laboratories (ABT $109.41)
- $109.41 P/E (TTM): 13.71X Cap: $190.05B
- View ABT Profile
- View Questions on ABT

Q: Hello, Abbott’s stock has dropped nearly 15% in the past month. Given their latest earnings report, would you continue holding ABT, or would you consider replacing it with another company in the same sector? If so, which two or three alternatives would you recommend for a long‑term investor? Thank you

Read Answer Asked by Gervais on January 28, 2026

Abbott Laboratories (ABT $109.41)
- $109.41 P/E (TTM): 13.71X Cap: $190.05B
- View ABT Profile
- View Questions on ABT

Q: Abbott Laboratories (ABT) sold off ~10–12% this morning after its earnings report and updated guidance. Is this business still worth holding despite the disappointing performance? What are your thoughts on its prospects? If you think ABT remains a good company based on the latest results, can you provide key valuation and profitability metrics such as forward P/E, PEG, ROE, and debt levels? Thanks.

Read Answer Asked by Adam on January 28, 2026

Gilead Sciences Inc. (GILD $142.89)
- $142.89 P/E (TTM): 21.97X Cap: $176.11B
- View GILD Profile
- View Questions on GILD
Abbott Laboratories (ABT $109.41)
- $109.41 P/E (TTM): 13.71X Cap: $190.05B
- View ABT Profile
- View Questions on ABT
Merck & Company Inc. (MRK $113.37)
- $113.37 P/E (TTM): 14.58X Cap: $281.38B
- View MRK Profile
- View Questions on MRK
Pfizer Inc. (PFE $26.66)
- $26.66 P/E (TTM): 15.37X Cap: $150.33B
- View PFE Profile
- View Questions on PFE

Q: Would you recommend starting a new position now in these big pharma stocks with rotation out of the tech sector lately? All three have decent PE, PEG and PS ratios and have been fared well in last few bear markets overall. What would your recommended allocation be across the three stocks for an investment of time line of 5 years?
Thanks!

Read Answer Asked by Scott on December 17, 2025